Opinion/decision on a Paediatric investigation plan (PIP): Tecartus, brexucabtagene autoleucel, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Neoplasms benign, malignant and unspecified (incl cysts and polyps), PIP number: P/0176/2024

Standard for exchange of non-clinical data (SEND): proof-of-concept study

Questions and answers about the SEND proof-of-concept for industry: Scope, terms of participation and data submission process

EMEA-001716-PIP07-22-M01

EMEA-001666-PIP02-21-M01

Questions and answers for biological medicinal products

Human medicines European public assessment report (EPAR): Yargesa, miglustat, Date of authorisation: 22/03/2017, Revision: 6, Status: Authorised

Human medicines European public assessment report (EPAR): Imvanex, smallpox and monkeypox vaccine (Live Modified Vaccinia Virus Ankara), Date of authorisation: 31/07/2013, Revision: 30, Status: Authorised

Register of deadlines to put a medicinal product on the market In accordance with Article 33 of the Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006

Human Medicines